In this article, we highlight some of the clinical characteristics of patients displaying HRG-ErbB3 pathway activation, which we believe identifies a novel clinical phenotype characterized by the persistence of highly drug-tolerant HRG-positive cancer cells within a heterogeneous tumor that directly impacts clinical outcomes following anticancer therapy. This evidence concerns the gene HRG and cancer.